Whereas it reveals a strong correlation between LFS latency, risk and variant neoantigenicity, it does not demonstrate an effective cancer protective or suppressive anti-mutant p53 T-cell response in patients with germline TP53 variants. This evidence concerns the gene TP53 and cancer.